Pink Slips for Genentech's Bay Area Employees
When Roche bought Genentech in March, layoffs were expected, and now the company has begun downsizing at Genentech?s South San Francisco headquarters.
When Roche bought Genentech in March, layoffs were expected, and now the company has begun downsizing at Genentech’s South San Francisco headquarters. So far the cuts have affected "less than one percent" of Genentech's 8,250 Bay Area employees, the company told the San Francisco Chronicle.
The reductions, which are occurring through a combination of voluntary buyouts and layoffs, focus on late-stage drug development and corporate administration, the Chronicle reported. There will be “little to no” job loss in manufacturing and all six of the Genentech’s manufacturing and distribution sites will stay open.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
